Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | SSTR3 | P32745 | 3/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13712272 | 0.87 | ALDH1A1 (0.45) | ACHEBACE1KDM4EALDH1A1BCHE | |
| SCHEMBL5394785 | 0.84 | HPGD (0.51) | ALDH1A1GRM2GRM3SSTR3 | |
| SCHEMBL5384594 | 0.84 | HPGD (0.51) | ALDH1A1GRM2GRM3SSTR3 | |
| SCHEMBL372599 | 0.84 | HPGD (0.51) | ALDH1A1GRM2GRM3SSTR3 | |
| SCHEMBL4485053 | 0.80 | SSTR3 (0.47) | SSTR3MMP13 | |
| SCHEMBL26641160 | 0.76 | ACHE (0.49) | ACHEBACE1KDM4EALDH1A1BCHE | |
| SCHEMBL14415190 | 0.76 | ALDH1A1 (0.49) | KDM4EALDH1A1NPC1SSTR3 | |
| SCHEMBL14492276 | 0.75 | ACHE (0.65) | ACHEBACE1KDM4EALDH1A1BCHE | |
| SCHEMBL4480119 | 0.75 | SSTR3 (0.63) | KDM4ESSTR3 | |
| SCHEMBL2500840 | 0.75 | SSTR3 (0.59) | KDM4EALDH1A1LMNANPC1SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582626-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090111798-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111798-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | HAVCR2, PYGL, HCCS | ACHE 1582/4885BACE1 2026/4885KDM4E 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.